Fig. 5: Impact of TRAF3 mutations in ultra-high risk myeloma patients. | Blood Cancer Journal

Fig. 5: Impact of TRAF3 mutations in ultra-high risk myeloma patients.

From: The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

Fig. 5

A Survival plot of the 13 ultrahigh-risk patients in our cohort showed that patients with TRAF3 mutations may have improved outcomes, although this did not reach significance in our series. However, the prognostic significance of TRAF3 mutations was later explored in the CoMMpass series for confirmation. B Globally, TRAF3 wild-type patients in the CoMMpass cohort had a significantly worse PFS compared to TRAF3 mutated patients. C From the CoMMpass series, patients that had a sFLCr > 100 at diagnosis and experienced disease progression at any time (N = 181) were selected. In this high-risk subpopulation, TRAF3 wild-type patients also showed dismal prognosis with a significantly shorter TTP. CI Confidence interval, bPFS biochemical progression-free survival, HR hazard ratio, PFS progression-free survival, TTP time to progression, WT wild type.

Back to article page